During the corresponding time, Aclarion Inc recorded a revenue increase by 30.48 % year on year, sequentially revenue grew by 19.24 %. While revenue at the Aclarion Inc 's corporate clients
Aclarion Inc's Comment on Sales, Marketing and Customers
Aclarion serves surgeons who treat patients with low back pain. Its first commercial product, NOCISCAN, utilizes proprietary biomarkers and algorithms to assist surgeons in identifying painful intervertebral discs, aiming to enhance surgical decision-making and patient outcomes. The company is commercializing this technology with the goal of establishing it as a standard protocol for surgical treatment planning in low back pain. Aclarion is also seeking insurance reimbursement through CPT codes. The market includes patients with low back and neck pain, which represent a significant healthcare burden in the United States and globally. The company has collaborations involving customers such as PHILIPS, which uses PHILIPS MRS capabilities with the NOCISCAN platform, and SIEMENS.
In a notable development within the healthcare technology sector, Aclarion Inc. announced that its pioneering product, Nociscan, has been highlighted in the RSNA (Radiological Society of North America) edition of Siemens’ MAGNETOM Flash. This recognition underscores the growing interest among leading physicians who are increasingly incorporating Nociscan into their clinical practices for managing chronic low back pain, a condition affecting millions worldwide.Nociscan is designed to enhance the assessment and treatment of chronic low back pain, an ailment often characterized by its complex nature and substantial variability in patient response to traditional treatments. As physicians integrate Nociscan int...
In a significant advancement within the field of surgical medicine, Aclarion Inc. has officially launched the Clinical Utility and Economic (CLUE) Trial. This innovative study aims to assess how frequently AI-generated biomarker data from Nociscan influences surgical treatment plans formulated by surgeons. The trial will focus on the clinical relevance of Nociscan’s unique capabilities in improving patient outcomes and adjusting treatment strategies.Under the clinical protocols of the CLUE Trial, surgeons will outline their initial surgical treatment plans prior to receiving any Nociscan data. Following the analysis of the AI-generated biomarker signals, they will report on how often and to what extent the...
In a significant stride in the management of chronic low back pain, Aclarion Inc s Nociscan solution is set to play a critical role in the groundbreaking LIFEHAB trial. The trial, based in Norway, is a randomized controlled exploration comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation. Notably, this innovative trial comes at a time when Aclarion Inc recorded an impressive year on year revenue increase of 59.91%. The substantial increment emphasizes the pivotal role of the Nociscan solution in driving the company s financial growth, bolstering the consistency and credibility of its market appeal. The Nociscan solution, offering clinical insight into chronic pain, will be utilized...
Aclarion Inc., a leading provider of surgical decision support technology, has recently forged a strategic partnership agreement with ATEC (Alpha Technology Company). The primary objective of this collaboration is to expedite the commercialization of Aclarion’s revolutionary NociScan platform and enhance spine surgery outcomes through ATEC s AlphaInformatiX platform. This groundbreaking alliance has the potential to revolutionize the field of spine surgery and improve patient care.Under the strategic partnership, Aclarion s state-of-the-art surgical decision support technology will be seamlessly integrated into ATEC s AlphaInformatiX platform. By leveraging artificial intelligence and machine learning algo...
Aclarion Inc’s Comment on Sales, Marketing and Customers
Aclarion serves surgeons who treat patients with low back pain. Its first commercial product, NOCISCAN, utilizes proprietary biomarkers and algorithms to assist surgeons in identifying painful intervertebral discs, aiming to enhance surgical decision-making and patient outcomes. The company is commercializing this technology with the goal of establishing it as a standard protocol for surgical treatment planning in low back pain. Aclarion is also seeking insurance reimbursement through CPT codes. The market includes patients with low back and neck pain, which represent a significant healthcare burden in the United States and globally. The company has collaborations involving customers such as PHILIPS, which uses PHILIPS MRS capabilities with the NOCISCAN platform, and SIEMENS.
Sources:
Aclarion Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Aclarion Inc’s corporate clients.
For your research, we’ve provided 9 tables on Aclarion Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
